The company ended 2024 with just under $127 million in cash reserves, and nothing in its pipeline beyond the Alzheimer's ...

Cassava Sciences has officially ended development of simufilam in Alzheimer’s disease, marking the end of a tumultuous era defined by controversy and failed clinical trials. The company reported the ...

Acrivon Therapeutics Inc. provided updated phase II data for checkpoint kinase candidate ACR-368, highlighting promising response rates for biomarker-positive patients with endometrial cancer and ...

Cassava is stopping all development of simufilam in Alzheimer’s disease. Image credit: Shutterstock / Mikadun. Cassava Sciences has officially stopped the development of its investigational drug ...

In October, Merck took up an option on the personalised RNA-based cancer vaccine with an upfront ... 2b results with regulators. The saga of Cassava Sciences' development of Alzheimer's disease ...

Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer’s disease Simufilam continued to ...

Cassava Technologies has announced plans to build Africa’s first “AI Factory” — a high-performance, AI-enabled data center powered by NVIDIA’s advanced computing technology. At the ...

Investment bankers say large pharma and biotech deals are stalling as executives grapple with mercurial White House economic ...

Cassava Technologies has tapped Nvidia to build Africa’s first artificial intelligence "factory". Cassava Technologies, founded by Zimbabwean telecommunications tycoon Strive Masiyiwa, has tapped ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...